<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483638</url>
  </required_header>
  <id_info>
    <org_study_id>TTD-11-01</org_study_id>
    <secondary_id>2011-002384-16</secondary_id>
    <nct_id>NCT01483638</nct_id>
  </id_info>
  <brief_title>Axitinib as Maintenance Treatment in Patients With Metastatic CRC</brief_title>
  <acronym>TTD-11-01</acronym>
  <official_title>A Phase II Study of Axitinib as Maintenance Treatment for Patients With Metastatic Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the maintenance therapy with axitinib in patients&#xD;
      with metastatic colorectal carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was prematurely closed due to lack of accrual&#xD;
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of disease response</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>axitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>axitinib</intervention_name>
    <description>5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>will be administered orally with the same schedule of axitinib</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have histological or cytological confirmed colorectal adenocarcinoma with&#xD;
             metastatic disease documented on diagnostic imaging studies, not susceptible of&#xD;
             radical surgery of metastases, and a low burden of disease.&#xD;
&#xD;
          2. Patients without progressive disease after six months of the standard first line&#xD;
             chemotherapy regimen for CRC (5FU or capecitabine ± oxaliplatin or irinotecan ±&#xD;
             bevacizumab or cetuximab).&#xD;
&#xD;
          3. Patient must have at least one measurable lesion as defined by modified RECIST&#xD;
             criteria.&#xD;
&#xD;
          4. Male or female, age ≥18 years.&#xD;
&#xD;
          5. ECOG performance status of 0 or 1 and life expectancy of ≥12 weeks.&#xD;
&#xD;
          6. Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  absolute neutrophil count (ANC) ≥1500 cells/mm3;&#xD;
&#xD;
               -  platelets ≥100,000 cells/mm3.&#xD;
&#xD;
               -  Hemoglobin ≥9.0 g/dL.&#xD;
&#xD;
               -  AST and ALT ≤2.5 x upper limit of normal (ULN), unless there are liver metastases&#xD;
                  in which case AST and ALT ≤5.0 x ULN;&#xD;
&#xD;
               -  Total bilirubin ≤1.5 x ULN;&#xD;
&#xD;
               -  Alkaline phosphatase &lt;300U/l&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥50 mL/min;&#xD;
&#xD;
               -  Urinary protein &lt;2+ by urine dipstick. If dipstick is ≥2+ then a 24-hour urine&#xD;
                  collection can be done and the patient may enter only if urinary protein is &lt;2 g&#xD;
                  per 24 hours.&#xD;
&#xD;
          7. At least 4 weeks since the end of prior systemic treatment, radiotherapy, or surgical&#xD;
             procedure with resolution of all treatment-related toxicity to NCI CTCAE Version 4.0&#xD;
             grade ≤1 or back to baseline except for alopecia or neurotoxicity&#xD;
&#xD;
          8. No evidence of pre existing uncontrolled hypertension as documented by 2 baseline&#xD;
             blood pressure readings taken at least 1 hour apart. The baseline systolic blood&#xD;
             pressure readings must be ≤140 mm Hg, and the baseline diastolic blood pressure&#xD;
             readings must be ≤90 mm Hg. Patients whose hypertension is controlled by&#xD;
             antihypertensive therapies are eligible.&#xD;
&#xD;
          9. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 3 days prior to treatment.&#xD;
&#xD;
         10. Signed and dated informed consent document indicating that the patient (or legally&#xD;
             acceptable representative) has been informed of all pertinent aspects of the trial&#xD;
             prior to enrollment.&#xD;
&#xD;
         11. Willingness and ability to comply with scheduled visits, treatment plans (including&#xD;
             willingness to take either AG-013736 or placebo according to randomization),&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Gastrointestinal abnormalities including:&#xD;
&#xD;
               -  inability to take oral medication;&#xD;
&#xD;
               -  requirement for intravenous alimentation;&#xD;
&#xD;
               -  prior surgical procedures affecting absorption including total gastric resection;&#xD;
&#xD;
               -  treatment for active peptic ulcer disease in the past 6 months;&#xD;
&#xD;
               -  active gastrointestinal bleeding, unrelated to cancer, as evidenced by&#xD;
                  hematemesis, hematochezia or melena in the past 3 months without evidence of&#xD;
                  resolution documented by endoscopy or colonoscopy;&#xD;
&#xD;
               -  malabsorption syndromes.&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal&#xD;
                  abscess within 6 months prior to start, unless affected area has been removed&#xD;
                  surgically&#xD;
&#xD;
          2. Current use or anticipated need for treatment with drugs that are known potent CYP3A4&#xD;
             inhibitors (ie, grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole,&#xD;
             erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir,&#xD;
             nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir and delavirdine).&#xD;
&#xD;
          3. Current use or anticipated need for treatment with drugs that are known CYP3A4 or&#xD;
             CYP1A2 inducers (ie, carbamazepine, dexamethasone, felbamate, omeprazole,&#xD;
             phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, and&#xD;
             St. John's wort).&#xD;
&#xD;
          4. History of haemorrhage within the past 6 months, including gross hemoptysis or&#xD;
             hematuria.&#xD;
&#xD;
          5. Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose&#xD;
             anticoagulants for maintenance of patency of central venous access devise or&#xD;
             prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular&#xD;
             weight heparin is allowed.&#xD;
&#xD;
          6. Active seizure disorder or evidence of brain metastases, spinal cord compression, or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
          7. A serious uncontrolled medical disorder or active infection that would impair their&#xD;
             ability to receive study treatment.&#xD;
&#xD;
          8. Any of the following within the 12 months prior to study drug administration:&#xD;
             myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft,&#xD;
             symptomatic congestive heart failure, cerebrovascular accident or transient ischemic&#xD;
             attack and 6 months for deep vein thrombosis or pulmonary embolism.&#xD;
&#xD;
          9. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2, atrial fibrillation of any grade,&#xD;
             or QTc interval &gt;450 msec for males or &gt;470 msec for females.&#xD;
&#xD;
         10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome&#xD;
             (AIDS)-related illness.&#xD;
&#xD;
         11. History of a malignancy (other than colorectal cancer) except those treated with&#xD;
             curative intent for skin cancer (other than melanoma), in situ breast or in situ&#xD;
             cervical cancer, or those treated with curative intent for any other cancer with no&#xD;
             evidence of disease for 2 years.&#xD;
&#xD;
         12. Dementia or significantly altered mental status that would prohibit the understanding&#xD;
             or rendering of informed consent and compliance with the requirements of this&#xD;
             protocol.&#xD;
&#xD;
         13. Female patients who are pregnant or lactating, or men and women of reproductive&#xD;
             potential not willing or not able to employ an effective method of birth&#xD;
             control/contraception to prevent pregnancy during treatment and for 6 months after&#xD;
             discontinuing study treatment. The definition of effective contraception should be in&#xD;
             agreement with local regulation and based on the judgment of the principal&#xD;
             investigator or a designated associate.&#xD;
&#xD;
         14. Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             drug administration, or may interfere with the interpretation of study results, and in&#xD;
             the judgment of the investigator would make the patient inappropriate for entry into&#xD;
             this study.&#xD;
&#xD;
         15. Current, recent (within 4 weeks of the study treatment administration), or planned&#xD;
             participation in an experimental therapeutic drug study other than this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Grávalos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Carrato, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spanish Cooperative Group for Digestive Tumour Therapy</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttdgroup.org</url>
    <description>Related info</description>
  </link>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>May 11, 2016</last_update_submitted>
  <last_update_submitted_qc>May 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>duration of disease response</keyword>
  <keyword>axitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

